Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Kava Pharma | Zion Development | N-Pharma | Piluet Georgia | Eco Resurs Nattek |
|---|---|---|---|---|---|
| Total Revenue | 8,427 | 5,362 | 5,179 | 4,985 | 3,276 |
| Total COGS | -7,426 | 0 | -1,983 | -4,378 | -1,998 |
| Gross Profit | 1,002 | 5,362 | 3,196 | 607 | 1,278 |
| Gross Margin | 11.9% | 100.0% | 61.7% | 12.2% | 39.0% |
| Total Operating Expenses | -611 | -4,251 | -1,786 | -920 | -701 |
| EBITDA | 390 | 1,112 | 1,409 | -314 | 576 |
| EBITDA Margin | 4.6% | 20.7% | 27.2% | -6.3% | 17.6% |
| Total D&A | -3 | -47 | -78 | -414 | -14 |
| EBIT / Operating Income | 387 | 1,065 | 1,331 | -727 | 562 |
| Total Interest Expense | -180 | -130 | -86 | -133 | -23 |
| Total Other Income | -151 | 89 | — | 2 | 25 |
| Profit Before Tax | 55 | 1,265 | 1,245 | -859 | 567 |
| Total Income Tax | 0 | 0 | -163 | 0 | -151 |
| Net Profit / (Loss) | 55 | 1,265 | 1,082 | -859 | 415 |
| Net Margin | 0.7% | 23.6% | 20.9% | -17.2% | 12.7% |
| Total Interest Income | — | 242 | — | — | 2 |
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| N-Pharma | Pharma | 27.2% | 70th pct | 110 |
| Zion Development | Pharma | 20.7% | 60th pct | 110 |
| Eco Resurs Nattek | Pharma | 17.6% | 54th pct | 110 |
| Kava Pharma | Pharma | 4.6% | 22nd pct | 110 |
| Piluet Georgia | Pharma | -6.3% | 6th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.